Share This Page
Suppliers and packagers for volnea
✉ Email this page to a colleague
volnea
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Xiromed | VOLNEA | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 202689 | ANDA | Bryant Ranch Prepack | 63629-2449-1 | 3 BLISTER PACK in 1 CARTON (63629-2449-1) / 1 KIT in 1 BLISTER PACK | 2017-12-01 |
| Xiromed | VOLNEA | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 202689 | ANDA | Xiromed, LLC. | 70700-122-85 | 3 CARTON in 1 CARTON (70700-122-85) / 1 BLISTER PACK in 1 CARTON (70700-122-84) / 1 KIT in 1 BLISTER PACK | 2017-12-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: VOLNEA
Introduction
Volnea (generic name: talazoparib) is an oral poly ADP-ribose polymerase (PARP) inhibitor primarily used in the treatment of adult patients with germline BRCA-mutated (gBRCA-mutated) locally advanced or metastatic breast cancer. As a targeted therapy, Volnea’s manufacturing and supply chain are critical for ensuring global availability. This comprehensive analysis details the current key suppliers, manufacturing landscape, and strategic considerations impacting Volnea’s supply chain.
Overview of Volnea and Its Market
Volnea, developed by pharmaceutical companies specializing in oncology therapeutics, entered the market around 2019. As a next-generation PARP inhibitor, it offers a treatment option with a unique mechanism of action for patients with specific genetic markers.
The primary markets for Volnea include North America, Europe, and select Asian countries. The drug’s specialty status limits its manufacturing to a limited number of qualified suppliers, reinforcing supply chain complexity.
Manufacturers and Supply Chain Stakeholders
Primary Manufacturer
Pfizer Inc.
Pfizer is the sole marketed producer of Volnea, owning the rights following licensing agreements with other biotech firms. The company's global manufacturing infrastructure is pivotal for the drug's availability across different markets. Pfizer’s extensive biopharmaceutical facilities in the United States, Europe, and Asia support Volnea’s production, with quality control adhering to stringent regulatory standards.
Manufacturing Facilities
Pfizer’s manufacturing footprint includes:
- United States: Strategic plants in Michigan and Puerto Rico equipped for sterile injectable and oral pharmaceutical production.
- Europe: Facilities in Belgium and the UK, catering to European market demand.
- Asia: Factories in Singapore and Japan to meet regional approval and distribution needs.
Third-party Contract Manufacturing Organizations (CMOs):
Pfizer partners with specialized CMOs for certain formulation steps, particularly in the late-stage development phase and for secondary packaging. Notable CMOs include Thermo Fisher Scientific and Lonza, which supply raw materials and assist in scaling manufacturing capacity.
Raw Material and Active Pharmaceutical Ingredient (API) Suppliers
The API for Volnea, talazoparib, is synthesized through high-precision chemical processes requiring specialized subcontractors.
- Key API Suppliers:
- Jiangsu Hengrui Medicine Co., Ltd. (China) - reportedly supplies intermediates or finished API components.
- BASF SE (Germany) – supplies critical chemicals used in API synthesis.
This reliance on regional chemical suppliers underscores the importance of robust quality assurance to meet global regulatory standards.
Regulatory and Quality Considerations
The pharmaceutical supply chain for Volnea must align with rigorous regulatory frameworks, including FDA regulations in the US, EMA standards in Europe, and MHRA compliance in the UK. Pfizer maintains these standards through its manufacturing practices, ensuring batch consistency, sterility, and stability.
Potential supply disruptions may arise from:
- Regulatory changes,
- Quality control issues,
- Raw material shortages,
- Geopolitical tensions affecting imports.
Distribution and Logistics
Distribution channels for Volnea are managed through Pfizer’s global logistics network to ensure rapid delivery to hospitals, specialty pharmacies, and clinics. Cold chain logistics are generally not required due to the drug’s storage stability, simplifying distribution.
Pharmaceutical wholesalers and specialty pharmacy networks are critical in ensuring broad accessibility, with regional distributors adapting to local regulatory frameworks.
Future Supply Chain Trends and Risks
1. Diversification Initiatives:
Pfizer and other pharmaceutical companies aim to diversify their API supply sources to mitigate geopolitical risks, especially dependency on Chinese and Indian chemical suppliers.
2. Supply Chain Transparency:
Pharma companies are increasingly adopting digital tracking tools and blockchain for better transparency and traceability of raw materials and finished products.
3. Capacity Expansion:
Pfizer continues investing in manufacturing capacity, particularly in Asia and Europe, to meet growing demand due to increased indications and market expansion.
4. Patent and Market Exclusivity:
Patent protections safeguard Pfizer’s market share, but looming patent cliffs could incentivize other manufacturers to develop biosimilar or generic equivalents, potentially entering the supply chain.
Emerging Suppliers and Competitive Landscape
Although Pfizer remains the sole commercial supplier, emerging biotech firms are exploring PARP inhibitors with similar mechanisms, potentially disrupting supply chains and competitive dynamics in the coming years. Strategic alliances between biotech startups and large pharma could influence future API sourcing and manufacturing.
Conclusion
The supply of Volnea hinges on Pfizer’s integrated manufacturing infrastructure, strategic partnerships with CMOs, and regional raw material suppliers. While Pfizer’s vast global footprint mitigates some risks, dependence on regional chemical suppliers introduces vulnerabilities. The evolving landscape emphasizes diversification, digital transparency, and capacity expansion to safeguard supply continuity amid market expansion and competitive pressures.
Key Takeaways
- Pfizer is the exclusive manufacturer of Volnea, supported by regional manufacturing facilities worldwide.
- Critical raw materials and API production largely depend on Chinese and European suppliers, necessitating risk mitigation strategies.
- Regulatory compliance and quality assurance are vital to maintaining supply stability.
- Supply chain resilience is enhanced through capacity investments and strategic partnerships with CMOs.
- Emerging competitors and biosimilars could influence future supply and market dynamics.
FAQs
1. Who are the primary suppliers for Volnea’s active pharmaceutical ingredient (API)?
The API for Volnea is primarily supplied by regional chemical manufacturers, notably Jiangsu Hengrui Medicine in China and BASF in Germany, which produce intermediates and chemicals essential for talazoparib synthesis.
2. Is Pfizer the sole manufacturer of Volnea globally?
Yes. Pfizer is the authorized and exclusive producer of Volnea, leveraging its extensive manufacturing network and quality standards.
3. What are the risks to Volnea’s supply chain?
Risks include dependency on regional chemical suppliers, regulatory delays, manufacturing disruptions, geopolitical tensions, and raw material shortages.
4. Are there any emerging competitors supplying similar PARP inhibitors?
While Pfizer holds exclusivity for Volnea, several biotech firms are developing alternative PARP inhibitors. These could introduce biosimilar competition or alternative supply options in the future.
5. How does Pfizer ensure supply chain resilience for Volnea?
Pfizer invests in capacity expansion, diversifies supplier relationships, collaborates with CMOs, and maintains rigorous quality controls to mitigate supply disruptions and meet global demand.
References
[1] Pfizer Official Website. "Volnea (talazoparib): Pharmacology and Supply Chain." Pfizer, 2023.
[2] European Medicines Agency. "Authorization Details for Volnea." EMA, 2022.
[3] Market Research Future. "Global PARP Inhibitors Market Analysis." MRFR, 2022.
[4] Industry Reports. "Supply Chain Strategies in Oncology Drugs," Pharma Supply Chain Review, 2022.
[5] Financial Analysts. "Pfizer’s Manufacturing Footprint and Capacity Investments," Bloomberg, 2023.
More… ↓
